BUZZ-血癌细胞疗法试验数据良好，Arcellx公司业绩攀升

Reuters12-09

((自动化翻译由路透提供，请见免责声明 ))

12月9日 - ** 细胞疗法开发商Arcellx 的股价盘前上涨8%至91.35美元

** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤（一种血癌）患者的中期试验中显示出97%的总体反应率 (link)

** 总体反应率是指对疗法有部分或完全反应的患者比例。

** 与吉利德公司合作开发的anito-cel如果获得批准，将与强生公司的细胞疗法Carvykti竞争。

** 券商 TD Cowen 称，anito-cel 的疗效至少与 Carvykti 相当，但安全性更高

** ACLX 的疗法没有显示出对神经系统的延迟损伤，但在试验期间有 3 人因不良事件死亡

** 截至上次收盘，股价累计上涨 52.3

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490252767?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-09 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490252767","market":"us","top_or_hot":-1,"title":"BUZZ-血癌细胞疗法试验数据良好，Arcellx公司业绩攀升","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    12月9日 - ** 细胞疗法开发商Arcellx  的股价盘前上涨8%至91.35美元</p><p>** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤（一种血癌）患者的中期试验中显示出97%的总体反应率 (link) </p><p>** 总体反应率是指对疗法有部分或完全反应的患者比例。</p><p>** 与吉利德公司  合作开发的anito-cel如果获得批准，将与<a href=\"https://laohu8.com/S/JNJ\">强生</a>公司  的细胞疗法Carvykti竞争。 </p><p>** 券商 TD Cowen 称，anito-cel 的疗效至少与 Carvykti 相当，但安全性更高 </p><p>** ACLX 的疗法没有显示出对神经系统的延迟损伤，但在试验期间有 3 人因不良事件死亡</p><p>** 截至上次收盘，股价累计上涨 52.3</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-血癌细胞疗法试验数据良好，Arcellx公司业绩攀升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-血癌细胞疗法试验数据良好，Arcellx公司业绩攀升\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 20:02 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    12月9日 - ** 细胞疗法开发商Arcellx  的股价盘前上涨8%至91.35美元** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤（一种血癌）患者的中期试验中显示出97%的总体反应率 (link) ** 总体反应率是指对疗法有部分或完全反应的患者比例。** 与吉利德公司  合作开发的anito-cel如果获得批准，将与强生...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2490252767","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490252767","pubTimestamp":1733745748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    12月9日 - ** 细胞疗法开发商Arcellx  的股价盘前上涨8%至91.35美元** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤患者的中期试验中显示出97%的总体反应率  ** 总体反应率是指对疗法有部分或完全反应的患者比例。** 券商 TD Cowen 称，anito-cel 的疗效至少与 Carvykti 相当，但安全性更高 ** ACLX 的疗法没有显示出对神经系统的延迟损伤，但在试验期间有 3 人因不良事件死亡** 截至上次收盘，股价累计上涨 52.3","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","JNJ":"强生","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","GILD":"吉利德科学","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4583":"猴痘概念","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU1732800096.USD":"摩根大通环球收益基金A (irc)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4559":"巴菲特持仓","ACLX":"ARCELLX, INC.","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU1261432733.SGD":"Fidelity World A-ACC-SGD","BK4504":"桥水持仓","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","BK4588":"碎股","BK4534":"瑞士信贷持仓","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4532":"文艺复兴科技持仓","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD"},"translate_title":"BUZZ-blood cancer cell therapy trial data is good, Arcellx's performance climbs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":0.9,"GILD":0.9,"JNJ":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    12月9日 - ** 细胞疗法开发商Arcellx  的股价盘前上涨8%至91.35美元** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤（一种血癌）患者的中期试验中显示出97%的总体反应率 (link) ** 总体反应率是指对疗法有部分或完全反应的患者比例。** 与吉利德公司  合作开发的anito-cel如果获得批准，将与强生公司  的细胞疗法Carvykti竞争。 ** 券商 TD Cowen 称，anito-cel 的疗效至少与 Carvykti 相当，但安全性更高 ** ACLX 的疗法没有显示出对神经系统的延迟损伤，但在试验期间有 3 人因不良事件死亡** 截至上次收盘，股价累计上涨 52.3","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490252767"}